Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- VKTX
- Price
- 34.09
- Stock movement up
- +0.71 (2.13%)
- Company name
- Viking Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.94B
- Ent value
- 3.85B
- Price/Sales
- -
- Price/Book
- 6.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 476.79%
- 1 year return (CAGR)
- 3.71%
- 3 year return (CAGR)
- 54.86%
- 5 year return (CAGR)
- 38.62%
- 10 year return (CAGR)
- 29.20%
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VKTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 6.16 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 115.55M |
| EPS (TTM) | -3.15 |
| FCF per share (TTM) | -2.44 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -320.00K |
| Operating income (TTM) | -393.34M |
| Net income (TTM) | -359.64M |
| EPS (TTM) | -3.15 |
| EPS (1y forward) | -4.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 165.81M |
| Net receivables | 0.00 |
| Total current assets | 715.60M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 85.00K |
| Total assets | 715.73M |
| Accounts payable | 53.25M |
| Short/Current long term debt | 137.00K |
| Total current liabilities | 76.67M |
| Total liabilities | 76.67M |
| Shareholder's equity | 639.06M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -278.69M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -278.69M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -56.28% |
| Return on Assets | -50.25% |
| Return on Invested Capital | -56.26% |
| Cash Return on Invested Capital | -43.60% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 33.45 |
| Daily high | 34.98 |
| Daily low | 33.26 |
| Daily Volume | 3.01M |
| All-time high | 94.50 |
| 1y analyst estimate | 92.72 |
| Beta | 0.79 |
| EPS (TTM) | -3.15 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 29 Apr 2026 |
Downside potential
Loading...
Downside potential data
| VKTX | S&P500 | |
| Current price drop from All-time high | -63.93% | -0.89% |
| Highest price drop | -90.41% | -56.47% |
| Date of highest drop | 2 Aug 2017 | 9 Mar 2009 |
| Avg drop from high | -59.78% | -10.84% |
| Avg time to new high | 82 days | 12 days |
| Max time to new high | 1151 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.94B
Marketcap category
Mid-cap
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Employees
53
Investor relations
SEC filings
CEO
Brian Lian
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page